Roth MKM lowered the firm’s price target on Curaleaf (CURLF) to $5 from $7 but keeps a Buy rating on the shares. The company reported a modest decrease in Q3 top-line growth but improved margins, as international revenue and operational emphasis inflects higher, the analyst tells investors in a research note. The firm adds however that attaining its EBITDA target will be dependent on international ramping, with improved 2025 utilization expected to drive margin improvement.
Don't Miss out on Research Tools:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CURLF:
- Curaleaf price target lowered to C$7.25 from C$8.50 at Canaccord
- Curaleaf downgraded to Market Perform from Speculative Buy at Cormark
- Curaleaf price target lowered to C$6.50 from C$11 at Alliance Global Partners
- Curaleaf Holdings Reports Q3 2024 Results
- Curaleaf Holdings Reports Steady Growth Amid Challenges